← All causality assessments
Expected pharmacological effect
Causality assessment · Expected pharmacological effect
Adenosine and Bronchospasm: is the FAERS signal real?
A written Bradford Hill assessment of one drug–event pair. The grade is a judgement about the signal, not a statement that this drug causes this event in any one person; FAERS counts are reports, not rates.
Adenosine ↔ Bronchospasm
n=41 co-reports · PRR 37.6 · ROR 38.6
Adenosine can precipitate bronchospasm by activating mast-cell and airway A2B receptors, a hazard in patients with asthma or obstructive lung disease; 41 co-reports give PRR 37.6. The label warns of respiratory difficulty and advises caution in bronchospastic disease.
Regulatory basis: adenosine (Adenocard) prescribing information — bronchospasm warning in bronchospastic disease.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Seconds after injection |
| Strength | met | PRR 37.6 with 41 co-reports |
| Consistency | met | Reproduced across reports |
| Specificity | met | Fairly specific to adenosine |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Known receptor-mediated bronchoconstriction |
| Coherence | met | Fits adenosine's airway effect |
| Experiment | n/a | Too rare/transient for trial capture |
| Analogy | met | Analogous to other bronchospastic triggers |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✗ No ClinicalTrials.gov results-posting trial in the top search hits for adenosine captured bronchospasm as a tracked adverse event in a usable structure. A brief procedural reaction is rarely coded as a structured adverse event in trials.